Floatz logo

nm32-2668

Mesothelioma, Malignant

Numab Therapeutics AGPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

28 Active assets in the Mesothelioma, Malignant cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Dr Jean Yannis PERENTES
Phase 2BB
Inno-206
Mayo Clinic
Phase 2BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2BB
Sargramostim
Memorial Sloan Kettering Cancer Center
Phase 2BB
TAMOXIFEN
Ottawa Regional Cancer Centre
Phase 2B

View all 50 →

Same molecule, other indications

nm32-2668 is also rated in:

lung adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
peritoneal carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
liposarcomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →